The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 years and older, with accelerated approval for those 65 and older.

Researchers evaluated the efficacy of secukinumab plus a glucocorticoid taper for achieving sustained remission in polymyalgia rheumatica.

Erica Schwartz, MD, MPH, JD, becomes the new CDC director as the nation faces surging measles cases and parasitic outbreaks.

In adults with type 2 diabetes, use of GLP-1 receptor agonists is associated with an increased risk for incident nonscarring alopecia.

Healthy plant-based diets are associated with lower CVD, T2D, and mortality risks regardless of food processing levels.

An overview of 5 FDA Priority Review PDUFA decision dates in September 2026, covering novel treatments in rare neurological disorders, oncology, and adolescent cardiology.

Vunakizumab provides rapid and sustained clinical improvement in plaque psoriasis regardless of disease duration or baseline disease severity.

Significant disproportionality signals have been identified for adverse drug events (ADEs) linked to apremilast, according to study results published in Experimental Dermatology.

Patients with Sjögren disease and lymphoid interstitial pneumonia may present with a distinct clinical phenotype and preserved pulmonary function.

Higher body mass index is linked to reduced odds of achieving minimal disease activity in psoriatic arthritis.

Regardless of patient ethnicity or socioeconomic status, disease activity improved over 6 months after the initiation of a tumor necrosis factor inhibitor for juvenile idiopathic arthritis.

Ultra-high frequency ultrasound of the labial salivary glands may accurately classify Sjögren disease and reduce the need for biopsy.